期刊
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
卷 1792, 期 7, 页码 625-633出版社
ELSEVIER
DOI: 10.1016/j.bbadis.2008.09.015
关键词
Leucine-rich repeat kinase 2; Dardarin; Neurodegeneration; Kinase; Movement disorder; Molecular genetic
资金
- NINDS NIH HHS [R00 NS058111-03, R00 NS058111] Funding Source: Medline
The frequency and potency of mutations in the LRRK2 gene redefine the role of genetic susceptibility in Parkinson's disease. Dominant missense mutations that fulfill initial criteria for potential gain of function mechanisms coupled with enzymatic activity likely amenable to small molecule inhibition position LRRK2 as a promising therapeutic target. Herein, key observations from the clinic to the test tube are highlighted together with points of contention and outstanding critical issues. Resolution of the critical issues will expedite the development of therapies that exploit LRRK2 activity for neuroprotection strategies. (C) 2008 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据